These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

747 related articles for article (PubMed ID: 25605840)

  • 1. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis.
    Teulings HE; Limpens J; Jansen SN; Zwinderman AH; Reitsma JB; Spuls PI; Luiten RM
    J Clin Oncol; 2015 Mar; 33(7):773-81. PubMed ID: 25605840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events.
    Chan L; Hwang SJE; Byth K; Kyaw M; Carlino MS; Chou S; Fernandez-Penas P
    J Am Acad Dermatol; 2020 Feb; 82(2):311-316. PubMed ID: 31233857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation-induced melanoma-associated leucoderma, systemic antimelanoma immunity and disease-free survival in a patient with advanced-stage melanoma: a case report and immunological analysis.
    Teulings HE; Tjin EP; Willemsen KJ; Krebbers G; van Noesel CJ; Kemp EH; Nieuweboer-Krobotova L; van der Veen JP; Luiten RM
    Br J Dermatol; 2013 Apr; 168(4):733-8. PubMed ID: 23421690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological basis of melanoma-associated vitiligo-like depigmentation.
    González R; Torres-López E
    Actas Dermosifiliogr; 2014 Mar; 105(2):122-7. PubMed ID: 23146137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy.
    Okamoto T; Irie RF; Fujii S; Huang SK; Nizze AJ; Morton DL; Hoon DS
    J Invest Dermatol; 1998 Dec; 111(6):1034-9. PubMed ID: 9856813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New perspectives on the role of vitiligo in immune responses to melanoma.
    Byrne KT; Turk MJ
    Oncotarget; 2011 Sep; 2(9):684-94. PubMed ID: 21911918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for the management of advanced melanoma: the next steps.
    Zikich D; Schachter J; Besser MJ
    Am J Clin Dermatol; 2013 Aug; 14(4):261-72. PubMed ID: 23516145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients.
    Zörnig I; Halama N; Lorenzo Bermejo J; Ziegelmeier C; Dickes E; Migdoll A; Kaiser I; Waterboer T; Pawlita M; Grabe N; Ugurel S; Schadendorf D; Falk C; Eichmüller SB; Jäger D
    Int J Cancer; 2015 Jan; 136(1):138-51. PubMed ID: 24839182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between cutaneous adverse events and prognosis in patients with melanoma treated with nivolumab: A single institutional retrospective study.
    Nakano E; Takahashi A; Namikawa K; Muto Y; Jinnai S; Kage Y; Mizuta H; Tsutsumida A; Yamazaki N
    J Dermatol; 2020 Jun; 47(6):622-628. PubMed ID: 32162349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic melanoma: spontaneous occurrence of auto antibodies is a good prognosis factor in a prospective cohort.
    Maire C; Vercambre-Darras S; Devos P; D'Herbomez M; Dubucquoi S; Mortier L
    J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):92-6. PubMed ID: 22145691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regression of nevi, vitiligo-like depigmentation and halo phenomenon may indicate response to immunotherapy and targeted therapy in melanoma.
    Farinazzo E; Zelin E; Agozzino M; Papa G; Pizzichetta MA; di Meo N; Zalaudek I
    Melanoma Res; 2021 Dec; 31(6):582-585. PubMed ID: 34433200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitiligo-like depigmentation and morpheas after specific intralymphatic immunotherapy for malignant melanoma.
    Lacour JP; Caldani C; Thyss A; Schneider M; Ortonne JP
    Dermatology; 1992; 184(4):283-5. PubMed ID: 1498395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
    Rosenberg SA; White DE
    J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):81-4. PubMed ID: 8859727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.
    Freeman-Keller M; Kim Y; Cronin H; Richards A; Gibney G; Weber JS
    Clin Cancer Res; 2016 Feb; 22(4):886-94. PubMed ID: 26446948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma as a model tumour for immuno-oncology.
    Maio M
    Ann Oncol; 2012 Sep; 23 Suppl 8():viii10-4. PubMed ID: 22918922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitiligo and Melanoma-Associated Vitiligo: Understanding Their Similarities and Differences.
    Cohen BE; Manga P; Lin K; Elbuluk N
    Am J Clin Dermatol; 2020 Oct; 21(5):669-680. PubMed ID: 32468356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case Report: Immune checkpoint inhibitor-related vitiligo-like depigmentation in non-melanoma advanced cancer: A report of three cases and a pooled analysis of individual patient data.
    Rao H; Guo Z; Wen X; Zeng X; Wu L; Huang L
    Front Oncol; 2022; 12():1099108. PubMed ID: 36713515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
    Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
    Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
    Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
    J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The many faces of autoimmune-mediated melanocyte destruction in melanoma.
    Ungureanu L; Vasilovici AF; Halmágyi SR; Trufin II; Apostu AP; Şenilă SC
    Front Immunol; 2024; 15():1417273. PubMed ID: 39421737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.